More handpicked essays just for you.
The importance of collaboration and teamworking in healthcare
Healthcare teams and collaboration
The importance of collaboration and teamworking in healthcare
Don’t take our word for it - see why 10 million students trust us with their essay needs.
Gilead Sciences, Inc., is a research-based biopharmaceutical company that discovers, develops, and produces marketable, innovative medicines in areas of under-addressed medical need on a global scale. Gilead 's vast array of products and production of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer and inflammation, and serious respiratory and cardiovascular conditions. Gilead’s product portfolio consists of a number of pharmaceutical firsts, including complete treatment regimens for HIV infection available in a once-daily pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Michael L. Riordan, MD, founded Gilead in 1987 in Foster City, California. Since then, they have grown to become one of the world’s largest biopharmaceutical companies, with more than 7,000 employees across six continents. Since it’s inception, the company has worked to contribute to the mission of advancing patient care by developing groundbreaking therapeutics to treat life-threatening diseases. According to Gilead’s website, they are “inspired by the opportunity to address unmet medical needs for patients living with
…show more content…
The several companies Gilead has acquired over the years has aided in their growth plan, however it is important to keep in mind that Gilead has always placed a very high value on partnering with companies and organizations whose strengths complement and augment their own. Over the past two decades, the company has cultivated collaborations with many academic institutions and biotechnology and pharmaceutical companies to develop innovative new therapeutics and advance the care of patients confronting life-threatening diseases. Collaborations with partners in science, academia, business and local communities, are considered central to Gilead’s
The multinational pharmaceutical firm, Wellcome PLC, brought a product to the market to help treat the symptoms of AIDS and HIV. Wellcome PLC owns an American subsidiary known as the Burroughs Wellcome Company. In 1987, Burroughs Wellcome Company received FDA approval to sale Retrovir, which interferes with the ability of HIV infected cells to produce new virus. Burroughs Wellcome Company finds itself under siege in September 1989 by AIDS activists and various segments of the U.S. government. Despite two reductions in price in the last two years, Burroughs Wellcome Company’s executive management is under unrelenting pressure to decrease the price of Retrovir so that many more people can afford the prescription.
Med-Pharmex Incorporated is known nationally and abroad as a pharmaceutical manufacturer of animal-related products. Before gaining fame worldwide, the business began its journey to success as a small lab in 1983, which slowly grew over time. Since then, the company maintains its main goal, and that is to produce drugs that promote the health of companion animals, such as dogs, cats, and horses, as well as food-producing animals, such as pork and chickens. To ensure legal responsibility, the company’s manufacturing process is examined by the United States Food and Drug Administration (FDA). Med-Pharmex works closely with veterinary clinics who purchase their life-saving drugs and represent them in the market. Despite manufacturing drugs, the
Background: Merck & Co. is an American pharmaceutical company and one of the largest pharmaceutical companies in the world. In 1971 the United States approved the use of an MMR vaccine made by Merck, containing the Jeryl Lynn strain of mumps vaccine. In 1978 Merck introduced the MMR II, using a different strain of the rubella vaccine. In 1997 the FDA required Merck to conduct effectiveness testing of MMRII. Initially it was over 95%; to continue the license; Merck had to convince the FDA that the effectiveness stayed at a similar rate over the years.
Being presented with the problems in the implementation of the SAP ERP system, it is evident that Novartis Pharmaceuticals requires a comprehensive action plan that resolves key issues and the underlying problem. Refer to Exhibit A for a graphical representation of the action plan.
Threat of new entrants is relatively high. Companies forming alliances are potential rivals. Even if earlier such company was not considered to be a threat, after merging with some research and development company or forming alliance with another pharmaceutical company it would become a rival to Eli Lilly. The threat is however weakened by significant research and development costs necessary to successfully enter the business. Eli Lilly’s focus on a relatively narrow market of sedatives and antidepressants weakens the threat of new entrants, but other products that form lesser part of company’s sales such as insulin and others are exposed to high threat of new entrants. The need of obtaining certificates and licenses also weakens the threat of new entrants. Discussed above leads to the conclusion that threat of new entrants is medium.
The United States has long been a leader in scientific research, but it will take industry, academia, and government working together for our country to stay there. Since the implementation of the Bayh-Dole Act of 1980, which gave universities greater control over intellectual property, research universities have teamed up with partners during early-stage development to further their resources. The new task of universities was not to conduct research with the intent to make money, but to present their findings to the public domain for the sake of knowledge and the public good. In 2004, David Sinclair and Christopher Westphal, two innovative scientists following their intuition, founded Sirtris Pharmaceuticals. The founding idea arose from Sinclair’s
Over the past decade, scientists have made significant advancements in the treatment of certain diseases. Unfortunately, just like any new product, the cost of developing these new technologies and treatments is extremely high. Plus, unlike other technology, heath technolo...
It will allow more opportunities for the Merck & Co. to innovate from. Not all great ideas are being generated within Merck and this strategy will allow us access to those other great ideas. Open innovation will help Merck jump back in the lead of developing the larger number of new pharmaceutical drugs. They have already dipped their toe in with the “reverse-merger” with Schering-Plough which was great way to introduce the idea to the organization and culture within Merck. This course of action is the most ethical because it allows the company to maintain its core strategy of differentiation. It will also help continue the reputation of being innovative by supplying more ideas to work with within the R&D department. It will create more possible drug choices for consumers and profits for the company to enjoy, especially shareholders. An external idea could help produce the next Nobel Prize for the R&D
...f ivermectin in the first place. Furthermore, we wouldn’t want to risk Merck going out of business, as it seems they had the capability to produce many useful medications. They’d already proved to make six useful, safe, and powerful drugs—the medical world wouldn’t want to lose such able creators. The best choice, therefore, would have Merck contributing to the research, but include other pharmaceutical companies and private donors to help with the financial and personnel costs. This funding would allow Merck and the other companies to sell at low costs, or even give, the medication to those who desperately need it. In order to implement such this type of plan, Merck would have to take the lead. They would have to actively seek out organizations, companies and private donors and explain the wonderful consequences for huge populations with the success of ivermectin.
Scherer, A. (2012) ‘M&A in Big Pharma: Holy Grail or Buying Time’, Contract Pharma, 21 Mar [Online]. Available at: http://www.contractpharma.com/contents/view_experts-opinion/2012-03-21/ma-in-big-pharma/#sthash.NnrBSo3O.dpuf (Accessed at: 15 December 2013)
Since its humble beginning as a small drugstore, Merck has placed a large amount of importance on improving the health and well-being of its customers. As drug patents expire and genetic forms of their top products become available, Merck’s strategy is to do the unexpected; instead of raising the price of their older products in favor of patent protected new drugs, Merck focuses on reducing their cost in order to better compete with their generic counterparts. Additionally, Merck’s plan for growth now encompasses a much more aggressive pursuit of new drugs in their pipeline through extensive research. Merck became the second largest health care company in the world after the merger with Schering-Plough in 2009 and has contributed great discoveries like the first cervical cancer vaccine and great resources like the Merck Manuals which are utilized as a source of information to doctors, scientists and consumers worldwide .
Rite Aid Corporation which ranks as the third largest retail drugstore chain in the United states, control about 2,380 drugstores in 28 states across professionals pharmacy service, a full selection of health and personal care products, an assortment of general products in the nation and in the District of Columbia ( Rite Aid, 2007 ). Rite Aid has a great management team to help them with their success their team includes Chairman, President and Chief Executive Officer, Special Advisor, Corporate Strategy ,Chief Operating Officer ,Chief Administrative Officer ,Executive Vice President – Pharmacy, Executive Vice President, Store Operations ,Executive Vice President and General Counsel( Rite Aid, 2007). Differentiate between management and leadership is very different for example, response to its huge losses, Rite Aid has said it expects to spend more than $94 million to reassess and restate its financial results for 1998 and 1999( ). Furthermore, that includes rerunning mainframe-based accounting systems and paying IT people overtime to work with internal and external accountants and auditors during the process. Still, Rite Aid does not plan to replace its combination homegrown Computer Corp. accounting system
With the increased cost of manufacturing, pharmaceutical companies have been divesting in their smaller or less profit making operations and focus on large segments. Many Pharmaceutical companies sold their manufacturing sites to contract manufacturing organizations. The dynamics of interfacing with contract manufacturing organization added intricacy in pharmaceutical supply chain network of pharmaceutical companies.
The case under analysis, Eli Lilly & Company, will be covering the positives and negatives with regards to the business situation and strategy of Eli Lilly. One of the major pharmaceutical and health care companies in its industry, Lilly focused its efforts on the areas of "drug research, development, and marketed to the following areas: neuroscience, endocrinology, oncology, cardiovascular disease, and women's health." Having made a strong comeback in the 1990's due to its remarkably successful antidepressant Prozac, was now facing a potential loss in profits with its patent soon to expire. The problem was not only the soon to expire patent on Prozac, but the fact that Prozac accounted for as much as 30% of total revenue was the reality Eli Lilly now faced. (Pearce & Robinson, 34-1)
The study of replication, transcription and translation of genetic material is known as molecular biology. Molecular biology is a bottom-up approach to understanding human life. Though the exploration of molecular biology began in the 1930s, it really took off in the 1960s after the uncovering of the structure of DNA. (Coriell Institute for Medical Research, n.d.) Today, molecular biology is shaping our understanding of diseases. Through this reflection journal, I seek to explore preventative and curative phenomena in medical biotechnology, and determine their impact on the political, social and economic spheres.